Early treatment with cyclosporin in serpiginous choroidopathy maintains remission and good visual outcome

Aim-To clinical outcomes of serpiginous choroidopathy treated primarily wit h cyclosporin at a tertiary uveitis referral centre. Methods-A case series of 14 eyes of seven patients with serpiginous choroid opathy with follow up ranging from 1.3 to 13 years is described. All patien ts had fundus lesions consistent with serpiginous choroidopathy, were inves tigated for systemic disease, had fluorescein angiography; and were treated with combined immunosuppressive therapy including cyclosporin. Results-No patients suffered significant loss of acuity after starting syst emic immunosuppression with cyclosporin as the primary agent. All but one p atient achieved remission and were able to stop medications with no recurre nces in the follow up period. Side effects from cyclosporin were well toler ated and there were no serious complications from immunosuppression. Conclusions-Cyclosporin is a safe and effective option with which to manage serpiginous choroidopathy. Significantly, adequate immunosuppression can r esult in clinical remission and cessation of therapy in some patients.